Filing Details

Accession Number:
0001479290-19-000036
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-03-19 20:58:46
Reporting Period:
2019-03-15
Accepted Time:
2019-03-19 20:58:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1479290 Revance Therapeutics Inc. RVNC Pharmaceutical Preparations (2834) 770551645
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1744573 Cyril Allouche C/O Revance Therapeutics, Inc.
7555 Gateway Blvd
Newark CA 94560
Principal Accounting Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-03-15 252 $15.45 6,898 No 4 F Direct
Common Stock Disposition 2019-03-18 498 $15.48 6,400 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 F Direct
No 4 S Direct
Footnotes
  1. Represents the number of shares withheld by and surrendered to the issuer on March 15, 2019, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock Award ("RSA") for 2,250 shares. The RSA vests in three equal annual installments from March 15, 2018, subject to Mr. Allouche's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Allouche.